Developed in collaboration with GSK, CV0501 is based on CureVac’s second-generation mRNA backbone and is designed to specifically protect against the Omicron variant. It is one of two second-generation candidates now in clinical trials from the German mRNA specialist, which withdrew its first-generation COVID-19 vaccine in 2021. Data from these two early-stage clinical trials will help CureVac select the best second-generation candidate for further development.
“Licensed COVID-19 vaccines that encode for the original virus variant, continue to protect against severe disease and hospitalization, but they are increasingly challenged by immune evasion of new variants such as Omicron,” said CureVac interim Chief Development Officer Dr. Ulrike Gnad-Vogt. “As we extend the clinical studies of our second-generation backbone into modified mRNA, targeting the Omicron variant will further explore the full potential of our improved second-generation design as a booster vaccination for a relevant variant.”
CureVac's two second-generation candidates
CV0501 is CureVac’s first COVID-19 vaccine candidate applying chemically modified mRNA from the COVID-19 vaccine. It encodes for the prefusion stabilized full-length spike protein of the SARS-CoV-2 Omicron variant and is formulated within lipid nanoparticles (LNPs). The vaccine was designed with specifically optimized non-coding regions to exhibit improved mRNA translation for increased and extended protein expression compared to the first-generation mRNA backbone.
The CV0501 study follows the start of a Phase 1 study in March 2022 that evaluates an unmodified second-generation COVID-19 vaccine candidate CV2CoV, encoding for the original virus variant.
In evaluating both an unmodified and a modified, second-generation vaccine candidate against COVID-19, CureVac expects to identify the best-performing candidate for later-stage clinical development. Data from both studies are expected to be reported as a combined data set.
CV0501’s Phase 1 dose-escalation study will be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines and is expected to enroll up to 180 healthy, COVID-19-vaccinated adults to evaluate the safety, reactogenicity and immunogenicity of a single booster dose of CV0501 in the dose range of 12µg to 50µg. Additional dose levels below 12µg and above 50µg may be evaluated if supported by safety and immunogenicity data at these dose levels.
COVID-19 studies are being conducted alongside CureVac and GSK’s jointly developed influenza vaccine program, in which clinical evaluation of the unmodified seasonal influenza candidate CVSQIV and the modified candidate FLU SV mRNA have similarly been initiated.
The CureVac-GSK infectious disease collaboration was first announced in July 2020. It focuses on the development of new products based on CureVac’s mRNA technology for different targets in the field of infectious diseases. The collaboration was extended in February 2021 to also include jointly developed vaccine candidates for COVID-19. In 2022, the companies broadened their development strategy to test modified mRNA technologies in addition to unmodified mRNA.
